Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

@inproceedings{Hoyos2010EngineeringCT,
  title={Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety},
  author={Valentina Hoyos and Barbara Savoldo and Concetta Quintarelli and Aruna Mahendravada and Ming Zhang and Juan Francisco L{\'o}pez Vera and Helen E Heslop and Cliona M Rooney and Malcolm K. Brenner and Gianpietro Dotti},
  booktitle={Leukemia},
  year={2010}
}
T lymphocytes expressing a chimeric antigen receptor (CAR) targeting the CD19 antigen (CAR.19) may be of value for the therapy of B-cell malignancies. Because the in vivo survival, expansion and anti-lymphoma activity of CAR.19+ T cells remain suboptimal even when the CAR contains a CD28 costimulatory endodomain, we generated a novel construct that also incorporates the interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15). We found that compared with CAR… CONTINUE READING
111 Citations
52 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 111 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I trial

  • R Brentjens, RIHDTCNYSJLJYRSESM
  • Mole Ther
  • 2010

Similar Papers

Loading similar papers…